Temsirolimus Plus Bortezomib Safe, Active for Relapsed/Refractory B-Cell NHL

the ONA take:

The combination of a mammalian target of rapamycin inhibitor and a proteasome inhibitor is safe and has activity in heavily pretreated patients with B-cell non-Hodgkin lymphoma, a recent study published in the journal Cancer has shown.

For the single-arm, phase 2 trial, researchers enrolled 39 patients with relapsed and refractory B-cell non-Hodgkin lymphoma.

The patients received bortezomib and temsirolimus weekly on days 1, 8, 15, and 22 of a 35-day cycle. This dosing scheme has previously been studied in patients with multiple myeloma.

Results showed that 7.7% of patients achieved a complete response and 23% achieved a partial response. Median progression-free survival was 4.7 months (2 months for patients with diffuse large B-cell lymphoma, 7.5 months for those with mantle cell lymphoma, and 16.5 months for those with follicular lymphoma).

Researchers found that two extensively treated patients with diffuse large B-cell lymphoma achieved a complete response. In regard to safety, there were no unexpected toxicities with the combination.

“Further studies with this combination are warranted in specific subtypes of NHL,” the authors conclude.

Temsirolimus Plus Bortezomib Safe, Active for Relapsed/Refractory B-Cell NHL
The combination of a mammalian target of rapamycin inhibitor and a proteasome inhibitor is safe in B-cell non-Hodgkin lymphoma.
Fenske, T. S., Shah, N. M., Kim, K. M., Saha, S., Zhang, C., Baim, A. E., Farnen, J. P., Onitilo, A. A., Blank, J. H., Ahuja, H., Wassenaar, T., Qamar, R., Mansky, P., Traynor, A. M., Mattison, R. J. and Kahl, B. S.
READ FULL ARTICLE From Wiley Online Library
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs